EGFR and colorectal carcinoma: Hence, based on different responses to epidermal growth factor receptor (EGFR)-targeted therapy (cetuximab), six CRC subtypes were characterized and associated with distinctive anatomical regions of the colon crypts (phenotype), with location-dependent differentiation states and Wnt signaling activity [32].